Cartesian Therapeutics Inc (NASDAQ: RNAC)’s stock price has soared by 21.86% in relation to previous closing price of $11.3. Nevertheless, the company has seen a gain of 26.45% in its stock price over the last five trading days. globenewswire.com reported 2025-06-03 that FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees. On June 2, 2025, the Company issued to these employees options to purchase an aggregate of 26,350 shares of the Company’s common stock with an exercise price of $9.98, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The options vest as to 25% on June 2, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on June 2, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees’ entry into employment with the Company.
Is It Worth Investing in Cartesian Therapeutics Inc (NASDAQ: RNAC) Right Now?
RNAC has 36-month beta value of 0.41. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for RNAC is 8.31M, and currently, short sellers hold a 31.62% ratio of that float. The average trading volume of RNAC on July 10, 2025 was 80.03K shares.
RNAC’s Market Performance
RNAC stock saw an increase of 26.45% in the past week, with a monthly gain of 24.78% and a quarterly increase of 36.20%. The volatility ratio for the week is 10.67%, and the volatility levels for the last 30 days are 8.26% for Cartesian Therapeutics Inc (RNAC). The simple moving average for the past 20 days is 28.39% for RNAC’s stock, with a -14.68% simple moving average for the past 200 days.
Analysts’ Opinion of RNAC
BTIG Research, on the other hand, stated in their research note that they expect to see RNAC reach a price target of $42. The rating they have provided for RNAC stocks is “Buy” according to the report published on December 19th, 2024.
RNAC Trading at 30.74% from the 50-Day Moving Average
After a stumble in the market that brought RNAC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.04% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RNAC starting from SPRINGER TIMOTHY A, who purchase 48,595 shares at the price of $10.47 back on Apr 10 ’25. After this action, SPRINGER TIMOTHY A now owns 620,175 shares of Cartesian Therapeutics Inc, valued at $508,751 using the latest closing price.
SPRINGER TIMOTHY A, the Director of Cartesian Therapeutics Inc, purchase 41,782 shares at $9.43 during a trade that took place back on Apr 09 ’25, which means that SPRINGER TIMOTHY A is holding 571,580 shares at $393,947 based on the most recent closing price.
Stock Fundamentals for RNAC
Current profitability levels for the company are sitting at:
- -1.53 for the present operating margin
- 0.99 for the gross margin
The net margin for Cartesian Therapeutics Inc stands at -1.12. The total capital return value is set at -0.13. Equity return is now at value -938.38, with -102.11 for asset returns.
Based on Cartesian Therapeutics Inc (RNAC), the company’s capital structure generated -1.82 points at debt to capital in total, while cash flow to debt ratio is standing at -2.19.
Currently, EBITDA for the company is -77.14 million with net debt to EBITDA at 4.15. When we switch over and look at the enterprise to sales, we see a ratio of 5.59. The receivables turnover for the company is 19.36for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.34.
Conclusion
To put it simply, Cartesian Therapeutics Inc (RNAC) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
